These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33433785)

  • 21. Glycopyrronium (Qbrexza) Topical Wipes for Hyperhidrosis.
    Arnold MJ; O'Connor C
    Am Fam Physician; 2019 Sep; 100(6):372-373. PubMed ID: 31524358
    [No Abstract]   [Full Text] [Related]  

  • 22. Topical glycopyrrolate reduces axillary hyperhidrosis.
    Baker DM
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2131-2136. PubMed ID: 27406319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mydriasis and anisocoria in a pediatric hyperhidrosis patient with interesting findings in the family cat.
    Sandhu M; Eisenstein K
    Pediatr Dermatol; 2023 Jan; 40(1):210-211. PubMed ID: 36263444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.
    Sechaud R; Machineni S; Tillmann HC; Hara H; Tan X; Zhao R; Ren S; Hou J
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):723-731. PubMed ID: 26428357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
    Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
    J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology, toxicology and clinical safety of glycopyrrolate.
    Chabicovsky M; Winkler S; Soeberdt M; Kilic A; Masur C; Abels C
    Toxicol Appl Pharmacol; 2019 May; 370():154-169. PubMed ID: 30905688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic anisocoria secondary to topical glycopyrronium for axillary hyperhidrosis: an emerging clinical presentation.
    Kaufman AR; Gulati S; Curnyn KM
    Can J Ophthalmol; 2020 Oct; 55(5):464. PubMed ID: 32735775
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic Mydriasis Secondary to Topical Glycopyrronium Tosylate Cloths: Clinical Characterization From a Multicenter Analysis.
    Kaufman AR; Gulati S; Pula JH; Janetos TM; Cherayil NR; Chiu E; Shepherd EA; Golnik KC; Garcia-Valenzuela E; MacIntosh PW; Johnson BT; Curnyn KM
    J Neuroophthalmol; 2022 Dec; 42(4):530-534. PubMed ID: 35427257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis.
    Paller AS; Shah PR; Silverio AM; Wagner A; Chamlin SL; Mancini AJ
    J Am Acad Dermatol; 2012 Nov; 67(5):918-23. PubMed ID: 22405644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of isolated axillary hyperhidrosis successfully treated topically with 1% glycopyrronium cream.
    Sega-Hall GM; Smith P; Haworth AE
    Clin Exp Dermatol; 2006 Nov; 31(6):825. PubMed ID: 17040271
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review.
    Cruddas L; Baker DM
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):952-963. PubMed ID: 27976476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine.
    Walling HW
    J Am Acad Dermatol; 2012 Mar; 66(3):387-92. PubMed ID: 21820204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of topical formulations containing 0ยท5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study.
    Masur C; Soeberdt M; Kilic A; Knie U; Abels C
    Br J Dermatol; 2020 Jan; 182(1):229-231. PubMed ID: 31218668
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
    D'Urzo AD; Kerwin EM; Chapman KR; Decramer M; DiGiovanni R; D'Andrea P; Hu H; Goyal P; Altman P
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1599-612. PubMed ID: 26316734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
    Bartels C; Looby M; Sechaud R; Kaiser G
    Br J Clin Pharmacol; 2013 Dec; 76(6):868-79. PubMed ID: 23506208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial.
    Szeimies RM; Abels C; Kilic A; Reich H; Berger B; Schulze Zur Wiesche E; Schramm K; Litzka L; Heimstaedt-Muskett S; Masur C
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):823-830. PubMed ID: 36606529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
    Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofpironium (Sofdra) for primary axillary hyperhidrosis.
    Med Lett Drugs Ther; 2024 Aug; 66(1709):133-134. PubMed ID: 39137175
    [No Abstract]   [Full Text] [Related]  

  • 39. Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate.
    Luh JY; Blackwell TA
    South Med J; 2002 Jul; 95(7):756-8. PubMed ID: 12144084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brella Sweat Control Patch for primary axillary hyperhidrosis.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):e125-e126. PubMed ID: 39137169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.